Estrella Immunopharma Stock Today
Estrella Immunopharma is selling for under 0.091 as of the 30th of November 2024; that is 3.53% up since the beginning of the trading day. The stock's lowest day price was 0.0879. Equity ratings for Estrella Immunopharma are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 3rd of June 2024 and ending today, the 30th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 14th of September 2021 | Category Healthcare | Classification Health Care |
Valuation Profit Patterns
Check how we calculate scores
Estrella Stock Highlights
| President CEO | Cheng Liu | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Financial Strength | |||||
Estrella Immunopharma can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Estrella Immunopharma's financial leverage. It provides some insight into what part of Estrella Immunopharma's total assets is financed by creditors.
| |||||
Estrella Immunopharma (ESLAW) is traded on NASDAQ Exchange in USA. It is located in 5858 Horton Street, EmeryVille, CA, United States, 94608 and employs 2 people. Estrella Immunopharma is listed under Biotechnology category by Fama And French industry classification. The company classifies itself under Biotechnology sector and is part of Health Care industry.
Estrella Immunopharma generates negative cash flow from operations
Check Estrella Immunopharma Probability Of Bankruptcy
Estrella Immunopharma Historical Income Statement
Estrella Stock Against Markets
Estrella Immunopharma Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Estrella Immunopharma stock to make a market-neutral strategy. Peer analysis of Estrella Immunopharma could also be used in its relative valuation, which is a method of valuing Estrella Immunopharma by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
Additional Tools for Estrella Stock Analysis
When running Estrella Immunopharma's price analysis, check to measure Estrella Immunopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Estrella Immunopharma is operating at the current time. Most of Estrella Immunopharma's value examination focuses on studying past and present price action to predict the probability of Estrella Immunopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Estrella Immunopharma's price. Additionally, you may evaluate how the addition of Estrella Immunopharma to your portfolios can decrease your overall portfolio volatility.